NASDAQ · KTTAW
Healthcare · Biotechnology
$0.00
Up+$0.00 (+14.29%)
Updated Sep 12, 2026, 12:34 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 7 trading sessions · Daily adjusted prices
KTTAW closed at $0.00 after 7 trading sessions, down 53.95% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.0035 | $0.0044 | $0.0035 | $0.0035 | 10.35K |
| Sep 9, 2026 | $0.0035 | $0.0035 | $0.0035 | $0.0035 | 52.82K |
| Sep 2, 2026 | $0.0035 | $0.0074 | $0.0035 | $0.0074 | 10.9K |
| Aug 31, 2026 | $0.0049 | $0.0049 | $0.0027 | $0.0027 | 30K |
| Aug 25, 2026 | $0.0051 | $0.0075 | $0.0051 | $0.0075 | 1.06K |
| Aug 24, 2026 | $0.0074 | $0.0074 | $0.0074 | $0.0074 | 1.2K |
| Aug 18, 2026 | $0.006 | $0.0076 | $0.006 | $0.0076 | 42K |
The latest Smart Investors Daily articles mentioning KTTAW.
KTTAW research
Company profile and research snapshot.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 1, 2021
-- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical professionals --
GlobeNewswire Inc. · Nov 29, 2021
MIAMI BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the closing of its previously announced private placement of common stock and warrants priced at a premium to the market under Nasdaq rules. The Company sold an aggregate of 8.68 million shares of common stock and warrants to purchase 8.68 million shares of common stock at a purchase price of $3.50 per share and accompanying warrant for gross proceeds to the Company of $30.4 million, before deducting the placement agent's fees and other estimated offering expenses.
GlobeNewswire Inc. · Nov 24, 2021
MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that it has entered into securities purchase agreements with certain institutional investors to purchase 8.68 million shares of its common stock and warrants to purchase 8.68 million shares of its common stock, at a purchase price of $3.50 per share and accompanying warrant in a private placement priced at a premium to the market under Nasdaq rules. The gross proceeds to the Company from the private placement are expected to be approximately $30.4 million before deducting the placement agent's fees and other estimated offering expenses.
GlobeNewswire Inc. · Nov 23, 2021
Pasithea Clinics is one of only three accredited clinics in the U.K. approved to offer esketamine nasal spray (SPRAVATO®) for treatment of mental health disorders Pasithea Clinics is one of only three accredited clinics in the U.K. approved to offer esketamine nasal spray (SPRAVATO®) for treatment of mental health disorders
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KTTAW.
No results
No recent SID articles mention KTTAW.
